A multicenter, randomized, open, controlled trial to evaluate the efficacy of Honglilai Vaginal Cream and Premarin Vaginal Cream for Genitourinary Syndrome of Menopause in different subgroups of Chinese postmenopausal women.
Gynecol Endocrinol
; 38(10): 861-867, 2022 Oct.
Article
en En
| MEDLINE
| ID: mdl-36067791
ABSTRACT
AIM:
In a randomized, multicenter, open, controlled trial, we compared the effects of Honglilai Vaginal Cream and Premarin Vaginal Cream in different age subgroups and menopausal year subgroups (trial registration numbers 02003L00493).METHODS:
Postmenopausal women with Genitourinary Syndrome of Menopause (GSM) were divided into Honglilai group (n = 319) and Premarin group (n = 116), while subgroups were divided according to their different characteristics of age and menopausal years. Honglilai Vaginal Cream (0.625 mg/g) or Premarin Vaginal Cream (0.625 mg/g) once daily for 3 weeks.RESULTS:
In the subgroup of participates >60 years, there were no significant differences of Vaginal Cell Maturation Index (VMI) between the two groups after treatment (p = .171). In the subgroup of 50-59 years, the VMI of Honglilai group was significantly lower than Premarin group (Honglilai group 74.37 ± 22.76; Premarin group 80.06 ± 16.15; p = .02). There were no significant differences of Vaginal symptom scores between Honglilai group and Premarin group in every sub-group (p > .05).CONCLUSIONS:
Honglilai Vaginal Cream had comparable efficacy with Premarin Vaginal Cream in Chinese women older than 60 years.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Cremas, Espumas y Geles Vaginales
/
Estrógenos Conjugados (USP)
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Gynecol Endocrinol
Asunto de la revista:
ENDOCRINOLOGIA
/
GINECOLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
China